Moderna’s COVID-19 vaccine produces immune response in early trial

The interim analysis of the phase 1 study of the candidate, mRNA-1273, evaluated a two-dose vaccination schedule of the shot given 28 days apart across three dosages – 25, 100, 250 µg – in 45 healthy adults aged 18-55 years. The initial results from participants who received both doses showed mRNA-1273 produced rapid and strong immune responses against SARS-CoV-2, the virus which causes COVID-19. Despite producing a promising immune response in all patients, the vaccine also caused side effects, including mild to moderate fatigue, chills, headache and muscle pain.PMLive